Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

RENAL_PHARM > RENAL CANCER PHARM > Flashcards

RENAL CANCER PHARM Flashcards

1
Q

what is the purpose of drugs in renal cancer

A

adjunctive therapy with surgery/radiation

alsowhere medical circumstances prevent surgery

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

what are the common sites for metastatic growth

A 
lymph nodes (most common)
lung, liver, bone (destructive lesions)
adrenal gland, Brain
opposite kidney
subq skin nodules
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Carboplatin MOA

A

platinum alkylating agent, forms DNA cross-links, resulting in inhibition of DNA synthesis and function

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

cyclophosphamide MOA

A

alkylating agent, forms DNA cross-links resulting in inhibition of DNA synthesis and function

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

doxorubicin MOA

A

anthracycline, oxygen free radicals bind to DNA causing strand breakage; inhibits topo II; intercalates DNA

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

dactinomycin MOA

A

antineoplastic action may involve binding to DNA by intercalation between base pairs and inhibition of DNA-dependent RNA synthesis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

etoposide, MOA

A

Podophyllotoxins, inhibits topoisomerase II, resulting in DNA damage

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

ifosfamide MOA

A

alkylating agent, nitrogen mustard, forms DNA cross links resulting in inhibition of DNA synthesis and function

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

vincristine MOA

A

Vinca alkaloids, inhibits microtubule assembly, halts mitosis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Aldesleukin; IL-2 MOA

A

Activates IL-2 receptors on t, B, and NK cells

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Bevacizumab MOA

A

VEGF inhibitor RESULTING IN INHIBITION OF TUMOR VASCULARIZATION

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Everolimus MOA

A

mTOR inhibitor, complex prevents protein synthesis and cell proliferation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

IFN-alpha MOA

A

antitumoral
direct antiproliferative effect on the tumor cell
induction of a host response to the tumor

also exert a cytostatic effect on tumor cells, slowing the rate of cell prliferation until cell survival is threatened

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Pazopanib MOA

A

VEGF tyrosine kinase inhibitor

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

sorafenib MOA

A

VEGF tyrosine kinase inhibitors

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

sunitinib MOA

A

VEGF tyrosine kinase inhibitors

17
Q

temsirolimus MOA

A

mTOR inhibitor

18
Q

carboplatin toxicity

A

myelosuppression; infection susceptibility

19
Q

cyclophosphamide toxicity

A

myelosuppression; hemorrhagic cystitits-MESNA

20
Q

doxorubicin toxicity

A

bone marrow suppression; acute and chronic cardiotoxicity

21
Q

dactinomycin toxicity

A

myelosuppression; hepatic dysfunction; infection susceptibility

22
Q

etoposide toxicity

A

hematologic toxicity; BP instability

23
Q

Ifosfamide toxicity

A

bone marrow suppression; hemorrhagic cystitits-MESNA

24
Q

VINCRISTINE toxicity

A

neurotoxicity; bilateral sensory stocking glove pattern

25
Q

rapamycins are what 2 drugs

A

temsirolimus and everolimus (mTOR inhibitors)

26
Q

what are the 3 main functions of the rapamycins

A

immunosuppressant effects
inhibition of cell-cycle prog. and angiogenesis
promotion of apoptosis

27
Q

Rapamycins bind to ____________ and inhibit mTORC1

A

FKBP12

28
Q

what drug prolongs survival and delays disease progression in pts with advanced and poor/intermediate risk renal cancer as compared to standard IFN-alpha treatement

A

temsirolimus

29
Q

what drug as compared to placebo, prolongs survival in pts who had failed initial treatment with anti-angiogenic drugs

A

everolimus

30
Q

temsirolimus is meabolized to what

A

sirolimus (daily oral drug)

31
Q

both temsirolimus and sirolimus are ___________substrates

A

CYP3A4

32
Q

Prominent side-effects of temsirolimus and sirolimus

A

mild maculopapular rash
mucositis
anemia
fatigue

(about 30-50% of pts)

RAP MY MUFFIN A FAT-ONE

33
Q

the VEGF TK inibitors are oral drugs that are metabolized by __________-

A

CYP3A4

34
Q

what are some sunitinib specific adverse effects

A 
fatigue
hypothyroidism
bone marrow suppression
CHF (often with HTN)
hand food syndrome

(SOME FAT HYPE BONES CAUSE HELL)

35
Q

what are some pazopanib specific effects

A

hepatic disease: severe and fatal hepatotoxicity

hyperbilirubinemia, especially in Gilbert’s syndrome

36
Q

the VEGF TK inhibitors inhibit also inhibit

A

2 other TK

37
Q

main safety concerns with bevacizumab include:

A 
hypertension
increased incidence of arterial thromboembolic events
wound healing complications
GI perforations
proteinuria
FATIGUE
38
Q

what are some adverse effects of aldesleukin; IL-2

A

capillary leak syndrome (extravasation of plasma proteins and fluid into the extravascular space leading to a loss of vascular tone)
decreased MAP and decreased organ perfusion

39
Q

what are some adverse effects of IFN-alpha

A

neuropsychiatric events, suicide, depression, relapse drug addiction

RENAL_PHARM (3 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions